Evaluation of anti-Candida potential of geranium oil constituents against clinical isolates of Candida albicans differentially sensitive to fluconazole: Inhibition of growth, dimorphism and sensitization

Mycoses

Volumn 54, Issue 4, 2011, Pages

  Zore, Gajanan B ^a   Thakre, Archana D ^a   Rathod, V ^a   Karuppayil, S Mohan ^a  

^a SWAMI RAMANAND TEERTH MARATHWADA UNIVERSITY   (India)

Author keywords

Candida albicans; Citronellol; Geraniol; Geranium oil; Geranyl acetate; Isoprenoids

Indexed keywords

CITRONELLOL; FLUCONAZOLE; GERANIOL; GERANYL ACETATE; PLANT EXTRACT;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SCREENING; DRUG SENSITIZATION; FEMALE; FUNGAL CELL; FUNGICIDAL ACTIVITY; GERANIUM; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

ACETATES; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; EPITHELIAL CELLS; GERANIUM; HELA CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MONOTERPENES; PLANT OILS; TERPENES;

CANDIDA; CANDIDA ALBICANS;

EID: 79959248083     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2009.01852.x     Document Type: Article

References (50)

1. Zhang H, Chen H, Niu J, Wang Y, Xie X. Role of Adaptive Immunity in the Pathogenesis of Candida albicans Keratitis. Invest Ophthalmol Vis Sci 2009; 50: 2653-9.
2. Biswas S, Dijck PV, Datta A. Environmental sensing and signal transduction pathways regulating morphopathogenic determinants of Candida albicans. Microbiol Mol Biol Rev 2007; 71: 348-76.
3. Ali AL, Banerjee U, Prasad R et al. Susceptibility pattern and molecular type of species-specific Candida in oropharyngeal lesions of Indian human immunodeficiency virus-positive patients. J Clin Microbiol 2004; 42: 1260-2.
4. Gaitan-Cepda LA, Martinez-Gonzalez M, Ceballos-Salobrena A. Oral Candidosis as a clinical marker of immune failure in patients with HIV/AIDS on HAART. AIDS Pat Care STDs 2005; 19: 70-77.
5. Kullberg BJ, Filler SG. Candidaemia. In: Calderone RA (ed.), Candida and Candidiasis. Washington, D. C: ASM Press, 2002: 327-40.
6. Pasqualotto AC, Rosa DD, Medeiros LR, Severo LC. Candidaemia and Cancer: patients are not all the same. BMC Infect Dis 2006; 6: 50-56.
7. Goa KL, Barradell LB. Fluconazole an update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995; 50: 658-90.
8. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12: 40-79.
9. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39: 1-8.
10. Albertson GD, Niimi M, Cannon RD, Jenkinson HF. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother 1996; 40: 2835-41.
11. Calabrese D, Bille J, Sanglard D. A novel multidrug efflux transporter gene of the major facilitator superfamily from Candida albicans (FLU1) conferring resistance to fluconazole. Microbiology 2000; 146: 2743-54.
12. Cowen LE, Sanglard D, Calabrese D et al. Evolution of drug resistance in experimental populations of Candida albicans. J Bacteriol 2000; 182: 1515-22.
13. Mukharjee PK, Chandra J, Kuhn DM, Ghannoum MA. Mechanism of fluconazole resistance in Candida albicans biofilms: phase specific role of efflux pumps and membrane sterols. Infect Immun 2003; 71: 4333-40.
14. Kremery V, Barnes AJ. Non-albicans Candida spp. causing fungemia, pathogenicity and antifungal resistance. J Hosp Infect 2002; 50: 243-60.
15. Chowdhary AR, Tripathi S. Application of essential oils in medicine. Fafai J 2002; 4: 43-48.
16. Cowan MM. Plant products as antimicrobial agents. Clin Microbiol Rev 1999; 12: 564-82.
17. Pichersky E, Gershenzon J. The formation and function of plant volatiles: perfumes for pollinator attraction and defense. Curr Opin Plant Biol 2002; 5: 237-43.
18. Deans SG. Evaluation of antimicrobial activity of essential (Volatile) oils, In: Linkens HF, Jackson JF (eds), Modern Methods of Plant Analysis, New Series vol. 12, 'Essential Oils and Waxes. Heidelberg: Springer-Verlag, 1991: 309-18.
19. Mo H, Elson CC. Studies on the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med 2004; 229: 567-85.
20. Devkatte AN, Zore GB, Karuppayil SM. Potential of plant oils as inhibitors of Candida albicans growth. FEMS Yeast Res 2005; 5: 867-73.
21. Ramage G, Saville SP, Wicks BL, Lopez-Ribot JL. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol 2002; 68: 5459-63.
22. Hammer KA, Carson CF, Riley TV. In-vitro activity of essential oils, in particular Melaleuca alternifolia (tea tree) oil and tea tree oil products, against Candida sp. J Antimicrob Chemother 1998; 42: 591-5.
23. Jain SK, Agrawal SC. Fungistatic activity of some perfumes against otomycotic pathogens. Mycoses 2002; 45: 88-90.
24. Abe S, Maruyam N, Hayama K et al. Suppression of TNF-α induced neutrophil adherence response by essential oils. Mediat Inflamm 2003; 12: 323-8.
25. Abe S, Maruyam N, Hayama K et al. Suppression of neutrophil recruitment in mice by geranium essential oils. Mediat Inflamm 2004; 13: 21-24.
26. Mondello F, Bernardis FD, Girolamo A, Salvatore G, Cassone A. In vitro and in vivo activity of tea tree oil against azole-susceptible and -resistant human pathogenic yeasts. J Antimicrob Chemother 2003; 51: 1223-39.
27. Mondello F, Bernardis FD, Girolamo A, Cassone A, Salvatore G. In vivo activity of terpinen-4-ol, the main bioactive component of Melaleuca alternifolia Cheel (tea tree) oil against azole-susceptible and -resistant human pathogenic Candida species. BMC Infect Dis 2006; 6: 158-65.
28. Lorenzi V, Muselli A, Bernardini A et al. Geraniol restores antibiotic activities against multidrug-resistant isolates from gram-negative species. Antimicrob Agents Chemother 2009; 53: 2209-11.
29. Carnesecchi S, Bradaia A, Fischer B et al. Purturbation by geraniol of cell membrane permeability and signal transduction pathways in human colon cancer cells. J Pharmacol Exp Therap 2002; 303: 711-5.
30. Carnesecchi S, Langley K, Exinger F, Gosse F, Raul F. Geraniol, a component of plant essential oils, sensitizes human colonic cancer cells to 5-Fluorouracil Treatment. J Pharmacol Exp Therap 2002; 301: 625-30.
31. Carnesecchi S, Schneider Y, Ceraline J et al. Geraniol, a component of plant essential oils, inhibits growth and polyamine biosynthesis in human colon cancer cells. J Pharmacol Exp Therap 2001; 298: 197-200.
32. Maruyama N, Sekimoto Y, Ishibashi H et al. Suppression of neutrophil accumulation in mice by cutaneous application of geranium essential oils. J Inflamm 2005; 2: 1-11.
33. Maruyama N, Takizawa T, Ishibashi H et al. Protective activity of geranium oil and its component, geraniol, in combination with vaginal washing against vaginal candidiasis in mice. Biol Pharm Bull 2008; 31: 1501-6.
34. Shoff SM, Grummer M, Yatvin MB, Elson CE. Concentration-dependent increase of murine P388 and B16 population doubling time by the acyclic monoterpene geraniol. Cancer Res 1991; 51: 37-42.
35. Ota Y, Hamada A, Nakano M, Saito H. Evaluation of percutaneous absorption of midazolam by terpenes. Drugs Metabol Pharmacokin 2003; 18: 261-6.
36. Bard M, Albrecht MR, Gupta N, Guynn CJ, Stillwell W. Geraniol interferes with membrane functions in strains of Candida and Saccharomyces. Lipids 1988; 23: 534-8.
37. Barry AL, Brown SD. Fluconazole disk diffusion procedure for determining susceptibility of Candida species. J Clin Microbiol 1996; 34: 2154-7.
38. Sandven P. Detection of Fluconazole-Resistant Candida Strains by a disc diffusion screening test. J Clin Microbiol 1999; 37: 3856-9.
39. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard-Second Edition. CLSI document M27-A2 [ISBN 1-56238-469-4]. Pennsylvania, USA: CLSI, 2002.
40. Manavathu EK, Curight JL, Loebenberg D, Chandrasekar PH. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56522). J Antimicrob Chemother 2000; 46: 229-34.
41. Mosel DD, Dumitra R, Horby JM, Atkin AL, Nickerson KW. Farnesol concentrations required to block germ tube formation in Candida albicans in the presence and absence of serum. Appl Environ Microbiol 2005; 71: 4938-40.
42. Alonso-Monge R, Navarro-Garcia F, Molero G et al. Role of the Mitogen-Activated Protein Kinase Hog1p in Morphogenesis and Virulence of Candida albicans. Antimicrob Agents Chemother 1999; 181: 3058-68.
43. Hall MJ, Middleton RF, Westmacott D. The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother 1983; 11: 427-33.
44. Krogstad DJ, Moellering RC Jr. Antimicrobial combinations. In: Lorian V (ed.), Antibiotics in Laboratory Medicine, 2nd ed. Baltimore: Williams & Wilkins, 1986: 537-95.
45. Freshney RI. Culture of animals cells. A manual of basic techniques, 5th edition (ISBN: 0-471-45329-3) 2005.
46. Brehm-Stecher BF, Johnsonl EA. Sensitization of Staphylococcus aureus and Escherichia coli to Antibiotics by the Sesquiterpenoids Nerolidol, Farnesol, Bisabolol, and Apritone. Antimicrob Agents Chemother 2003; 47: 3357-60.
47. Jabra-Rizk MA, Meiller TF, James CE, Shirtlif ME. Effect of Farnesol on Staphylococcus aureus Biofilm formation and antimicrobial susceptibility. Antimicrob Agents Chemother 2006; 50: 1463-9.
48. Tsuchiya H. Biphasic membrane effects of capsaicin, an active component in capsicum species. J Ethno-Pharmacol 2001; 75: 295-9.
49. Ernst JF. Transcription factors in Candida albicans environmental control of morphogenesis. Microbiology 2000; 146: 1763-74.
50. Butler PJ, Tsou T, Li JY, Usami S, Chien S. Rate sensitivity of shear induced changes in the lateral diffusion of endothelial cell membrane lipids: a role for membrane perturbation in shear-induced MAPK activation. FASEB J 2002; 16: 216-8.